GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $59.33.

Several research firms recently weighed in on WGS. The Goldman Sachs Group raised their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company lifted their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 1,137 shares of GeneDx stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the transaction, the chief financial officer now directly owns 24,731 shares of the company’s stock, valued at $1,888,706.47. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 2,154 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40. Following the completion of the sale, the chief executive officer now directly owns 105,426 shares of the company’s stock, valued at $7,021,371.60. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,123,603 shares of company stock worth $83,300,382 in the last three months. Company insiders own 27.30% of the company’s stock.

Institutional Trading of GeneDx

A number of institutional investors have recently added to or reduced their stakes in WGS. Bank of New York Mellon Corp acquired a new position in GeneDx during the 2nd quarter worth approximately $991,000. nVerses Capital LLC acquired a new position in shares of GeneDx during the second quarter worth $50,000. Rhumbline Advisers boosted its stake in shares of GeneDx by 8,096.4% in the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock valued at $480,000 after purchasing an additional 18,136 shares during the period. Acadian Asset Management LLC acquired a new stake in GeneDx during the 2nd quarter valued at $34,000. Finally, American Century Companies Inc. increased its stake in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after buying an additional 4,573 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $79.14 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx has a one year low of $2.63 and a one year high of $89.11. The firm has a market capitalization of $2.17 billion, a P/E ratio of -25.45 and a beta of 2.03. The company’s fifty day moving average is $76.28 and its two-hundred day moving average is $51.22.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. The firm’s revenue was up 44.3% on a year-over-year basis. Analysts forecast that GeneDx will post -0.24 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.